Skip to Content

  • Search

View Additional Section Content

A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB001, ELN115727) in Subjects with Alzheimer’s Disease who Participated in Study ELN115727-301 or in Study ELN115727-302

Principal Investigator(s)
David Weisman, M.D.
Brad Klein, M.D. (Sub-Investigator)
Lee Harris, M.D. (Sub-Investigator)

Clinical Trial Categories

  • Alzheimer's Disease
Contact
Jennifer McGowan at 215-327-0161

Location

  • Abington Neurological Associates, Ltd

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a Test
Request an Appointment

215-481-EXAM

Clinical Trials Details